Normal bacterial flora in canine and feline uteri.
Explore the source record for details and available documents.
Biomedical subjects
Publications and source records attributed to M L Kesel.
Explore the source record for details and available documents.
OBJECTIVE: To determine energy expenditure (EE) of apparently resting, client-owned dogs with malignant or nonmalignant diseases that were recovering from anesthesia and surgery, and compare those values with values from clinically normal, apparently resting, client owned dogs. ANIMALS: 40 apparently resting, client-owned dogs that had been given general anesthesia for various elective and nonelective surgical procedures, and 30 apparently resting, clinically normal client-owned dogs used as controls. PROCEDURE: EE was determined, using an open-flow indirect calorimetry system. Each dog was evaluated before and after surgery (0, 1, 2, and 3 days after surgery, then at suture removal > 14 days later) and compared with apparently resting, clinically normal, client-owned dogs (n = 30). Parameters evaluated were rate of oxygen consumption (Vo2/kg of body weight: ml/min/kg; Vo2/kg0.75: ml/min/kg0.75), EE (EE/kg: kcal/kg/d; EE/kg0.75: kcal/kg0.75/d), and respiratory quotient. RESULTS: Surgery and anesthesia did not significantly alter any of these parameters at any time assessed in any group. The pretreatment Vo2 and EE were significantly lower in the dogs with cancer, compared with dogs of other groups. CONCLUSIONS: These data suggest that the EE of a restricted group of dogs that undergo anesthesia and surgery for malignant and nonmalignant conditions does not increase from baseline values or when compared with values in clinically normal, client-owned dogs. CLINICAL RELEVANCE: This information may be of value when planning nutritional treatment for dogs recovering from anesthesia and surgery.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Feline and human mucopolysaccharidosis VI (MPS VI or Maroteaux-Lamy syndrome) are inherited autosomal recessive deficiencies of lysosomal enzyme arylsulphatase B. Affected cats and children exhibit lesions caused by incompetent degradation, retinal atrophy and excessive urinary excretion of dermatan facial dysmorphia, corneal stromal opacities, leukocyte granulation, retinal atrophy and excessive urinary excretion of dermatan sulphate--and usually die before adulthood. Most attempts to treat humans affected with MPS VI or other mucopolysaccharidoses have been ineffective or logistically prohibitive, but allogeneic bone marrow transplantation (BMT) offers promise for cure of certain inborn errors of metabolism. Engraftment of normal donor marrow may endow the enzyme-deficient recipient with a continuous source of enzyme-competent blood cells and tissue macrophages to facilitate degradation of stored substrate and to prevent genesis of further malformations. To test this hypothesis, we performed allogeneic BMT in a 2-year-old male Siamese cat with advanced MPS VI. Here we describe BMT-induced correction of this hereditary enzyme deficiency.